U.K. becomes the first to sequence 100,000 whole human genomes at scale for healthcare, opening up new opportunities for precision medicine

December 5, 2018
Consumer Choices in Food, Health, and Wellness More...
13275 thumb square
by Nardev Ramanathan
Very important

The U.K. has become the first nation in the world to sequence 100,000 human genomes at scale for healthcare, in partnership with Illumina. The 100,000 Genomes Project has already benefited patients by identifying rare genetic mutations in children that are otherwise difficult to diagnose by standard tests, allowing timely and effective interventions that save lives. Business opportunities clearly exist in public-private partnerships, as this success story with Illumina and the U.K. illustrates. This development will spur other global precision medicine initiatives, offering similar business opportunities for clients. Precision medicine is in Lux's 19 for 2019; clients should consider public-private partnership as a market access strategy.

For the original news article, click here .

Further Reading

A lack of Asian genomic data creates business opportunities today and tomorrow

Analyst Insight | August 28, 2018

Two out of every three people on this planet live in Asia. This doesn't even include the ethnic Asians living elsewhere or those of mixed ancestries. Interestingly, genomic efforts have hardly kept up with this demographic reality. In fact, Asian genomic data is scarce, with over 80% of genomic data... Not part of subscription

NovogeneAIT Genomics

Company Profile | September 12, 2018

Next‑generation sequencing (NGS) vendor providing high‑throughput genome sequencing services in a CAP‑certified laboratory and liquid biopsy‑based cancer diagnostics Core differentiation lies in having access to a strong IP portfolio in NGS processes and analyses and providing services in a ... Not part of subscription


Company Snapshot | April 12, 2018

The company was started by Peter Foley to connect customers to laboratories for home health testing. To date, the company has raised about $12 million in a Series A led by Optum Ventures in March 2018. The company develops home test kits for general health, sexual health, fertility, and cancer ... Not part of subscription